Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated, ER-Positive, HER2 ...

18 September 2026 · By · Wire by Fusion42

Published

18 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at oncnursingnews.com →

◆ Verified

Fusion42 · 18 September 2026 · Fusion42 review

The FDA approved the combination of imlunestrant and abemaciclib for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progression on endocrine therapy, supported by the EMBER-3 clinical trial results.

This Wire brief sits within Fusion42's coverage of Biotech, and 10 sources have reported it between 18 Sep 2026 and 21 Sep 2026.

◆ ◆ The Wire takeaway

You now have a new oral treatment to offer ER-positive breast cancer patients with ESR1 mutations, but you must integrate FDA-authorized genetic testing into your clinical workflow immediately to identify eligible patients.

◆ Coverage

10 sources · first reported 18 Sep 2026 · latest 21 Sep 2026

◆ Topics

Biotechfda-approvalbreast-canceresr1-mutationoral-therapyclinical-trial